TPN-101 for Progressive Supranuclear Palsy

Overview

TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder["@nct"].

Trial Details

Overview

TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder["@nct"].

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT04993768 |
| Status | Phase 2a (Completed) |
| Phase | Phase 2a |
| Sponsor | Translational Research Industries (TRI) |
| Study Design | Open-label, preliminary safety and tolerability |
| Intervention | TPN-101 oral administration |
| Enrollment | Approximately 40 participants |
| Condition | Progressive Supranuclear Palsy |

Mechanism of Action

Tau Pathology in PSP

TPN-101 targets the core pathological mechanism in PSP: the abnormal metabolism and aggregation of tau protein. PSP is classified as a primary 4R-tauopathy[@irwin2013].

The therapeutic approach reflects the growing understanding of tau propagation as a prion-like process[@sweeney2017]:

TPN-101's Proposed Mechanism

• Modulate tau protein metabolism: Interfere with abnormal tau processing
• Reduce pathological tau species: Lower levels of hyperphosphorylated tau
• Protect neuronal function: Support microtubule stability

Scientific Rationale

Tau as a Therapeutic Target

The tau hypothesis in PSP is strongly supported by multiple lines of evidence[@boxer2020]:

Comparison with Other Tau-Targeted Approaches

| Approach | Examples | Advantages |
|----------|----------|------------|
| Small Molecules | TPN-101, LMTM | Oral bioavailability |
| Active Immunization | AADvac1 | Long-lasting immunity |
| Passive Immunization | ABBV-8E12, E2814 | High specificity |

PSP Disease Background

Clinical Features

PSP manifests with multiple core symptoms[@stamelou2019]:

• Vertical supranuclear gaze palsy (VSGP): Difficulty with downward eye movements
• Postural instability: Frequent falls, typically backward
• Parkinsonism: Bradykinesia, rigidity (axial > limbs)
• Cognitive dysfunction: Frontal executive impairment
• Dysphagia: Swallowing difficulties leading to aspiration risk

Clinical Subtypes

| Subtype | Prevalence | Key Features |
|---------|------------|--------------|
| Richardson's syndrome (PSP-RS) | ~50% | Classic presentation |
| PSP-parkinsonism (PSP-P) | ~25% | Better levodopa response |
| PSP-corticobasal syndrome (PSP-CBS) | ~10% | Cortical sensory loss |
| Pure akinesia with gait freezing (PAGF) | ~5% | Predominant gait freezing |

Neuropathology

The hallmark lesion is neurofibrillary tangles composed of hyperphosphorylated 4R-tau. Key regions affected include[@lees2017]:

• Substantia nigra pars compacta: Dopaminergic neuron loss
• Globus pallidus: Tau accumulation
• Brainstem nuclei: Colliculi, oculomotor nucleus

Current PSP Treatment Landscape

Symptomatic Treatments

Current management is primarily supportive:

• Levodopa: Modest benefit in some PSP-P patients
• Botulinum toxin: For dystonia
• Physical therapy: Gait and balance training
• Speech therapy: For dysphagia management

Disease-Modifying Therapies in Development

• Tau Aggregation Inhibitors: Tolfenamic acid, Lithium
• Immunotherapies: Bepranemab, ABBV-8E12
• Neuroprotective Agents: CoQ10, TPN-101

Clinical Trial Design Considerations

Challenges in PSP Trials

PSP clinical trials face unique challenges[@litvan2011]:

Outcome Measures

• PSP Rating Scale (PSPRS): 36-item disease severity scale
• MDS-UPDRS: Motor and total scores
• Clinical Dementia Rating (CDR): Cognitive assessment

Significance of TPN-101

Regulatory Considerations

The FDA has granted orphan drug designation to several PSP therapies, providing:

• 7 years of market exclusivity upon approval
• Tax credits for clinical trials
• Priority review for serious conditions

Tau Biology and Therapeutic Targets

Tau Protein Structure and Function

The tau protein is encoded by the [MAPT](/genes/mapt) gene on chromosome 17q21 and plays critical roles in neuronal physiology:

Isoforms: Alternative splicing produces six tau isoforms in the adult human brain:

• 0N, 1N, 2N (based on N-terminal inserts)
• 3R, 4R (based on microtubule-binding repeat number)

• Microtubule stabilization and assembly
• Axonal transport facilitation
• Neuronal plasticity regulation
• DNA protection

• Phosphorylation at >45 sites
• Acetylation, methylation, ubiquitination
• Truncation and citrullination
• O-GlcNAcylation

Tau Aggregation in PSP

PSP is characterized by 4R-tau filament accumulation:

Neurofibrillary Tangles (NFTs):

• Paired helical filaments (PHF) and straight filaments
• Composed of hyperphosphorylated tau
• Distinct progression pattern from AD

• Neuronal tangles and threads
• Glial tau pathology (tufted astrocytes, coiled bodies)
• Neuropil threads in affected regions

• Templated seeding (prion-like)
• Exosomal transport
• Trans-synaptic transmission

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Tau Protein](/proteins/tau)
• [Tau Therapeutics Pipeline](/therapeutics/tau-therapeutics-pipeline)
• [MAPT Gene](/genes/mapt)
• [4R-Tauopathies](/mechanisms/4r-tauopathies)

External Links

• [NCT04993768 on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04993768)
• [CurePSP Foundation](https://curepsp.org/)
• [Movement Disorder Society](https://www.movementdisorders.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving TPN-101 for Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis: